Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00397
|
|||||
| Drug Name |
Vindesine
|
|||||
| Synonyms |
3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; 3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine; DAVA; Desacetylvinblastine amide; Lilly 112531; Methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate; Vindesin; Vindesina; Vindesina [INN-Spanish]; Vindesine (USAN/INN); Vindesine [USAN:BAN:INN]; Vindesine [USAN:INN:BAN]; Vindesinum; Vindesinum [INN-Latin]
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute lymphoblastic leukemia [ICD11: 2B33.0] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C43H55N5O7
|
|||||
| Canonical SMILES |
CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
|
|||||
| InChI |
InChI=1S/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1
|
|||||
| InChIKey |
HHJUWIANJFBDHT-KOTLKJBCSA-N
|
|||||
| CAS Number |
CAS 59917-39-4
|
|||||
| Pharmaceutical Properties | Molecular Weight | 753.9 | Topological Polar Surface Area | 165 | ||
| Heavy Atom Count | 55 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
2.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
102853537
, 103504328
, 104335455
, 126686646
, 127301247
, 127301248
, 127301249
, 127301250
, 127301251
, 127301252
, 127301253
, 127301254
, 127301255
, 127301256
, 127301257
, 127301258
, 127301259
, 127301260
, 127301261
, 127301262
, 127301263
, 127301264
, 127301265
, 127301266
, 127301267
, 127301268
, 127301269
, 127301270
, 127301271
, 127301272
, 127301273
, 127301274
, 127301275
, 127301276
, 127301277
, 127301278
, 134338223
, 14937951
, 24712319
, 34706568
, 46504548
, 47207961
, 48416698
, 50063064
, 53788169
, 57312475
, 77478141
, 7980884
, 8176819
, 92309091
|
|||||
| ChEBI ID |
ChEBI:32295
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.